Analyst consensus rating
Scribe Therapeutics Analyst Rating: none
Direct answer
Scribe Therapeutics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $57.00.
Forecast evidence checked October 27, 2026.
Get free Scribe Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $15.96
- Average price target
- $57.00
- High price target
- $60.00
- Low price target
- $50.00
- Low target gap
- +213.3%
- Target upside
- +257.1%
- High target gap
- +275.9%
- Target range width
- 62.7%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Scribe Therapeutics?
Scribe Therapeutics has a verified none consensus. The same dataset has an average price target of $57.00.
How far are Scribe Therapeutics's low and high targets from the recorded price?
The low target implies +213.3%, while the high target implies +275.9%.
How many analysts are included in Scribe Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Scribe Therapeutics's target upside or downside calculated?
The average target of $57.00 is divided by the recorded price of $15.96, then one is subtracted to produce +257.1%. This does not guarantee a future return.
When was Scribe Therapeutics's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.